Personal Genome Diagnostics
3600 Boston Street
Suite 10
Baltimore
Maryland
21224
United States
Website: http://www.personalgenome.com/
Email: info@personalgenome.com
67 articles about Personal Genome Diagnostics
-
Personal Genome Diagnostics CE Marks Liquid Biopsy Test
3/14/2019
PGDx elio™ plasma resolve liquid biopsy panel brings a local, non-invasive, clinical Next-Generation Sequencing (NGS) solution to Europe
-
Personal Genome Diagnostics Welcomes New Members to Board of Directors, Bringing Proven, Industry-Leading Experience in Precision Medicine and Healthcare Policy
2/27/2019
Two new additions deepen Board expertise and will be critical to driving the PGDx vision of empowering local, standardized Next Generation Sequencing, impacting cancer patients globally
-
Personal Genome Diagnostics and PathGroup Enter Co-Development Agreement to Accelerate the Availability of Comprehensive Genomic Profiling with TMB
1/7/2019
Partnership brings together innovative genomic technology with pathology expertise and real-world insights, enabling greater testing solutions that can inform critical treatment decisions for patients
-
International Clinical Trial Utilizes Personal Genome Diagnostics’ Liquid Biopsy Assay to Enroll Patients based on POLE/POLD1 status as a Predictor of Response to Immunotherapy
10/9/2018
Study examines PGDx technology as an innovative, non-invasive approach with the potential to reduce need for tumor biopsies
-
Machine Learning Approach by Personal Genome Diagnostics Outperforms Existing Mutation Detection Methods According to Study in Science Translational Medicine
9/5/2018
Peer-reviewed research using PGDx software demonstrates importance of high-quality somatic mutation detection in clinical next-generation sequencing
-
Personal Genome Diagnostics’ PGDx elio™ Plasma Resolve Receives Breakthrough Device Designation from FDA
7/24/2018
Personal Genome Diagnostics Inc. today announced that PGDx elio™ plasma resolve has received Breakthrough Device designation from The Center for Devices and Radiological Health (CDRH) of the U.S. Food and Drug Administration (FDA).
-
Personal Genome Diagnostics' TMB Analysis Used in Groundbreaking NEJM Study Showing Promising Checkpoint Inhibitor Efficacy in Early Stage Lung Cancer
4/19/2018
Personal Genome Diagnostics Inc. reported that its whole exome analysis platform contributed to an important new study published in the New England Journal of Medicine (NEJM) showing promising efficacy for a leading checkpoint inhibitor in early stage lung cancer.
-
Personal Genome Diagnostics Expands Its Tumor Mutational Burden (TMB) Patent Portfolio for Cancer Immunotherapy
2/28/2018
Personal Genome Diagnostics Inc. (PGDx) today announced an agreement with Memorial Sloan Kettering Cancer Center (MSK) for developing, registering, and commercializing products and services that include tumor mutation burden (TMB) biomarker status.
-
PGDx is a leader in the development of tissue-based and liquid biopsy technologies and products for cancer genomics.
-
U.S. Dept. of Veterans Affairs Renews and Expands Cancer Testing Contract With Personal Genome Diagnostics
11/10/2017
The contract includes PDGx's CancerSELECT 125 tissue and PlasmaSELECT64 liquid biopsy profiling panels.
-
Personal Genome Diagnostics Awarded Department Of Veterans Affairs Contract For Its PlasmaSELECT Liquid Biopsy Cancer Profiling Assay
6/14/2017
-
Personal Genome Diagnostics Highlights Its Patent-Pending Microsatellite Instability Testing Technology As FDA Approves Keytruda For MSI Tumors
6/2/2017
-
Personal Genome Diagnostics' Expanded PlasmaSELECT 64 Is First Liquid Biopsy Pan-Cancer Profiling Panel To Include MSI Analyses For Immuno-Oncology
3/28/2017
-
Personal Genome Diagnostics Announces Expanded Cancer Testing Contract With U.S. Department Of Veteran Affairs
3/22/2017
-
Personal Genome Diagnostics Awarded NCI Contract To Develop Novel Diagnostic For Immuno-Oncology Drugs
2/1/2017
-
Personal Genome Diagnostics Release: Company Adds James Lewis As Senior Vice President Of Corporate Development
1/17/2017
-
Personal Genome Diagnostics' ImmunoSELECT Technology Demonstrates How Resistance To Checkpoint Blockade Therapy Evolves In Cancer Discovery Study
1/4/2017
-
Personal Genome Diagnostics Launches CancerSELECT 125 Test For Pan-Cancer Tumor Profiling
12/19/2016
-
Personal Genome Diagnostics Launches RNAcomplete Allowing Co-Extraction And Analysis Of RNA And DNA From A Single FFPE Tissue Sample
10/24/2016
-
Personal Genome Diagnostics Licenses Rights To Microsatellite Instability (MSI) Testing Technology From Johns Hopkins University To Inform Immunotherapy
10/20/2016